Striverdi
Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog
An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
GSK’s Nucala approved by MHRA for uncontrolled COPD
Symptoms of COPD include breathlessness, persistent cough and frequent chest infections
GSK and Hengrui enter multi-programme collaboration agreement worth $12bn
The deal includes a PDE3/4 inhibitor in clinical development for COPD
Merck to expand respiratory disease portfolio with $10bn Verona acquisition
The deal includes a drug approved in the US for chronic obstructive pulmonary disease
UK researchers uncover first new asthma and COPD attack treatment in 50 years
The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings
Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD
Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease
GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD
The chronic respiratory disease affects more than 300 million people globally
Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults
Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment
Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease
Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation